about
(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesHuman bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuliConstitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies.Phase II study of sorafenib in patients with relapsed or refractory lymphoma.Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.Role of alpha-synuclein in autophagy modulation of primary human T lymphocytesCell therapy: achievements and perspectives.Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.Biology and clinical applications of marrow mesenchymal stem cells.Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathwaysSynergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanomaTargeting TRAIL agonistic receptors for cancer therapy.Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells.Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders.The role of inflammation in lymphoma.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature.A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.Forced expression of RDH10 gene retards growth of HepG2 cells.Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection.Ex vivo expansion of hematopoietic cells and their clinical use.Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells.Umbilical cord blood as a source of hematopoietic stem cells: from research to clinical application.T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM).Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-alpha: evidence for a tyrosine-kinase-dependent process.Stem cells and stem cell transplantation.Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.
P50
Q28488869-22E3616E-A80B-4F6F-9952-1732A87A5AE9Q29618769-0829D0F6-BBC7-4A4B-9009-3732177B9EFCQ30571484-47AD39E4-8863-4BEA-BD0E-2A30A00AE9D9Q33401136-6AA7C633-0868-450D-A955-BCF0D8CBE09FQ33417756-FFA7E277-78AC-4287-9144-A9F9D7B2CF6DQ33420273-DADCA9C7-A436-49FD-AC58-8A1E2CF75309Q33433659-72ED083A-89C9-42D4-945A-45AB849F043AQ33720362-14C47FB2-FEFB-4E27-869E-8018C30B84AFQ33787260-C4AE8EE9-238D-4359-A2EB-492C8CB79E75Q35584266-D4773C92-C54C-4C51-850B-A4C2CA0E0539Q36076550-C011E717-0F23-4F60-96F7-73AFDB92181BQ36184769-8C6B75F4-C718-43CE-8839-81090FA056BDQ36291134-5CE1F5DC-7F4E-4AA7-BB63-B805D7E1BC10Q36793399-B47BAE29-7738-4F35-A1F9-48F265A08684Q37204220-EA0D9F9D-E79E-4D9E-BE9A-6408990A871CQ38160322-65E56229-8C5C-4E5C-8317-CB913E11BAA4Q38211083-0C4F9223-804F-4B6F-9B9C-7D7746A56FC9Q38368587-D03FD5D2-49F5-4857-94D3-006684583CA6Q38466376-07BAB7A2-D633-410E-8449-95E195B63CCEQ38557033-2770EAE9-48D6-4EEE-ACB4-20DAF3DE9535Q38930717-B25486AE-DD6F-424B-BCEF-CA1F67E15C63Q39021652-FF4644ED-B33C-4D9B-840B-CBC06EEFECBDQ39162763-0CC65025-0D8F-4923-8653-DCF3F039910FQ39263090-9BAEB475-5085-48ED-8A06-4032D7E09E6EQ39649423-4CC99942-B8FD-43F0-8A58-8B676631FE69Q39682910-CE154E09-7F9B-4D6E-AC33-A47FD910462CQ39751817-F2C35567-DD48-43BE-A3F7-89DAEE75A6C6Q39817181-ECC70277-3D6F-4D42-A62F-D1D7C22D8D99Q40149288-2D66A295-0B38-4CE0-8299-AC6A1A9648E4Q40183970-4220C535-D438-4342-8FBD-5CAA672175B9Q40386808-B148A85A-D8BB-4170-8FF5-7DC803BF0F06Q40605448-E2125986-F245-4C1E-9880-68C85DF66792Q40834639-D2D4AA49-092E-416B-B699-3CF03747A7D3Q40923246-C2FD3AC2-A72A-4FC7-A779-3F49FD415F30Q40949214-1AC5BC74-5263-4B5E-AD3F-065C73654107Q41138074-3A298B17-898A-43AD-9D5E-845E21B3379FQ41266648-DF8153E1-F534-4FBC-A246-7A6D16292767Q41282297-B3C545E5-2D5E-4F80-968E-F2E093041C74Q41330071-6BE41B24-0401-43BC-87E3-D18B98283885Q41484569-E38C7EA2-7B99-4174-806F-E11E6DB7F6DB
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carmelo Carlo-Stella
@ast
Carmelo Carlo-Stella
@en
Carmelo Carlo-Stella
@es
Carmelo Carlo-Stella
@nl
Carmelo Carlo-Stella
@sl
type
label
Carmelo Carlo-Stella
@ast
Carmelo Carlo-Stella
@en
Carmelo Carlo-Stella
@es
Carmelo Carlo-Stella
@nl
Carmelo Carlo-Stella
@sl
prefLabel
Carmelo Carlo-Stella
@ast
Carmelo Carlo-Stella
@en
Carmelo Carlo-Stella
@es
Carmelo Carlo-Stella
@nl
Carmelo Carlo-Stella
@sl
P106
P1153
21033667600
P21
P31
P496
0000-0003-3144-0124